CLINICAL_TRIALS
trial_result
· 2014-09-16
Clinical Trial Update: Evaluation of ACCS100 to Reduce Aflatoxin Exposure in Kenya [Phase 2]
Summary
A Phase 2 trial evaluating ACCS100 to reduce aflatoxin exposure in Kenya has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Kenya Medical Research Institute | Conditions: Aflatoxicosis | Phase 2 | Status: COMPLETED